马来酸桂哌齐特联合奥拉西坦治疗血管性痴呆的临床观察

发布时间：2018-06-07 14:19

本文选题：马来酸桂哌齐特 + 奥拉西坦　；参考：《中国药房》2015年23期

【摘要】：目的:观察马来酸桂哌齐特联合奥拉西坦治疗血管性痴呆的临床疗效及安全性。方法:选取血管性痴呆患者62例,按随机数字表法分为治疗组和对照组,各31例。对照组患者给予奥拉西坦静脉滴注,4 g/d,连续治疗3周。治疗组患者在对照组基础上加用马来酸桂哌齐特静脉滴注,160 mg/d,连续治疗3周。两组患者均于治疗前、后通过简易精神状态评估量表(MMSE)及日常生活能力量表(ADL)进行评估。结果:两组患者治疗后MMSE及ADL评分与本组治疗前比较,差异有统计学意义(P0.05);治疗后治疗组MMSE评分及ADL各项评分改善情况优于对照组,差异有统计学意义(P0.05);两组患者均未出现明显不良反应。结论:马来酸桂哌齐特联合奥拉西坦能够显著改善血管性痴呆患者MMSE、ADL评分,提高患者的生活质量,临床效果显著且安全性良好。
[Abstract]:Objective: to observe the efficacy and safety of cinepazide maleate combined with olaxetam in the treatment of vascular dementia. Methods: 62 patients with vascular dementia were randomly divided into treatment group (n = 31) and control group (n = 31). Patients in the control group were treated with oxiracetam 4 g / d for 3 weeks. The patients in the treatment group were treated with cinepazide maleate 160 mg / d for 3 weeks on the basis of the control group. The patients in both groups were evaluated by MMSE and ADL before and after treatment. Results: there was significant difference in MMSE and ADL scores between the two groups after treatment compared with those before treatment, and the improvement of MMSE scores and ADL scores in the treatment group was better than that in the control group. The difference was statistically significant (P 0.05), and there were no significant adverse reactions in both groups. Conclusion: cinepazide maleate combined with olaxetam can significantly improve the MMSE ADL score and improve the quality of life of patients with vascular dementia.
【作者单位】：哈尔滨医科大学附属第四医院老年病科;
【分类号】：R749.13

【参考文献】